


**Kirk Kee**

MBBS, is an advanced trainee in respiratory and sleep medicine, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Victoria. k.kee@alfred.org.au

Matthew T Naughton

MD, FRACP, is Associate Professor, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Victoria.



Sleep apnoea

A general practice approach

Background

Snoring and sleepiness are common presentations in general practice.

Objective

To describe the frequency, clinical findings, investigations and management options for obstructive sleep apnoea.

Discussion

Obstructive sleep apnoea should be considered in a range of presentations. Diagnosis is based on history, examination, investigation and, occasionally, a trial of therapy. Management options should start with lifestyle management. Further options include surgery, dental splints and continuous positive airway pressure. Continuous positive airway pressure requires long term input by both the patient and the general practitioner. Common issues with the use of machines for the management of sleep apnoea are also discussed.

■ **Snoring and sleepiness are common symptoms presenting to general practice. In the United States of America, 60% of subjects consecutively surveyed in a primary care setting presented with symptoms of an underlying sleep disorder.¹ In Australia, 6% of patients reported visiting a doctor for a problem of sleep apnoea or snoring.²**

It is estimated that more than 60% of adults occasionally snore and more than 30% regularly snore,³ and that obstructive sleep apnoea (OSA) occurs in approximately 10% of females and 25% of males, of whom 2 and 4% respectively have OSA with sleepiness – the OSA syndrome.^{4,5} In children, 12% snore regularly⁶ and 2% have OSA.⁷ Given the rise in obesity and reductions in sleep time, the prevalence of sleep related symptoms, snoring, and OSA are likely to have increased in both children and adults.⁸


The term 'OSA syndrome' is used to describe the constellation of recurrent apnoeas (ie. absence of airflow for >10 seconds) or hypopnoeas (ie. reductions in airflow >10 seconds, sufficient to cause a fall in oxygen saturation or arousal from sleep) occurring at least five times per hour and associated with snoring and symptoms of day time sleepiness or fatigue.⁹ On a sleep study report, the total number of apnoeas and hypopnoea in an hour is given as the apnoea-hypopnoea index (AHI). An AHI ≥ 5 is considered significant.

Pathophysiology

Upper airway collapse due to sleep related loss of muscle tone (or inadequate muscle tone due to elevated nasal resistance) associated with a small oropharyngeal area (*Figure 1*) is considered the cause of most cases of OSA. In recent years, greater consideration has been paid to subconscious arousals and an altered central 'controller' of respiration causing transient reductions in respiratory drive. This culminates in an oscillation of apnoeas and/or hypopnoeas with hyperpnoeas which, with an unstable upper airway, will appear 'obstructive', whereas in other circumstances, with a patent upper airway, these may contribute to 'periodic breathing'.¹⁰ This latter form of sleep apnoea is seen at high altitude, in premature infants and in



Figure 1. Balancing forces required to maintain upper airway patency. Variables include airway size, muscle tone and neural control



adults with cardiac failure (Cheyne-Stokes respiration), stroke, renal failure, chronic narcotic use and/or diabetic ketoacidosis.

Snoring with less than five events per hour (AHI <5) has often been classified as benign, however there is evidence suggesting it may contribute to premature atherosclerosis of the carotid artery – presumably due to local vibrational damage, as the femoral artery does not appear to be affected.¹¹ In the long term, this may contribute

to cerebrovascular events. Moreover, regardless of the AHI, other family members may be disturbed by the snoring, which therefore may warrant treatment.

When to investigate

In the primary care setting, the following groups should be considered for a sleep study.

Loud noisy snoring

Loud noisy snoring defined as noise sufficiently loud enough to cause disruption to another person's sleep on a regular basis. Snoring is associated with greater divorce rates¹² – no small matter when one considers the value of the family unit in terms of cost effective delivery of housing, education and health care. Patients with any of the following snoring habits should be referred for assessment by a sleep physician:

- sufficient to disturb partner more than three nights per week
- audible in other rooms
- occurs despite alcohol abstinence
- occurs in lateral sleep position, or
- occurs >10% of the night.

Table 1. Epworth Sleepiness Scale

The following questions refer to sleepiness or the tendency to doze off when relaxed.

How likely are you to doze off or fall asleep in the following situations, in contrast to just feeling tired? This refers to your usual way of life in the past 3 months. Even if you haven't done some of these things recently, try to work out how they would have affected you.

Choose the most appropriate number for each situation by putting an X in one box for each question.

Situation	(0) Would never doze	(1) Slight chance of dozing	(2) Moderate chance of dozing	(3) High chance of dozing
1. Sitting and reading	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Watching TV	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Sitting, inactive in a public place (eg. at the theatre or a meeting)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. As a passenger in a car for an hour without a break	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Lying down to rest in the afternoon when circumstances permit	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Sitting and talking to someone	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Sitting quietly after a lunch (without having had alcohol)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. In a car, while stopped for a few minutes in traffic	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Total = _____/24

Score: 1–6 = adequate sleep; 7–8 = average sleep; >9 = abnormal sleep



Neurocognitive impairment

By definition, excessive day time sleepiness due to OSA should be considered when it occurs despite adequate sleep volume and following exclusion of other common causes of sleepiness such as depression, anaemia, medication side effects, or electrolyte disturbance. Sleepiness can be a subtle symptom and use of the Epworth Sleepiness Scale is a good guide (*Table 1*). Untreated OSA is associated with motor vehicle collisions, often confounded by chronic sleep deprivation and circadian factors.¹³ Judgment, speed and accuracy, personality change, memory loss and scholastic performance can also be affected.^{14,15}

Cardiovascular disease prevention

Increasing evidence suggests that untreated OSA is associated with greater cardiovascular disease (CVD), similar in proportion to that seen with cigarette smoking. Untreated OSA is associated with 2–4 fold increased chance of cardiovascular events in the community,^{16,17} and clinic^{18,19} populations. Despite this strong association between OSA and CVD, the effect size of OSA treatment on subsequent development of CVD is unknown.


Established cardiovascular disease

High risk populations are those with systemic hypertension taking more than two medications, nocturnal angina, congestive heart failure (especially with orthopnoea and/or paroxysmal nocturnal dyspnoea), stroke,¹⁸ atrial fibrillation and chronic obstructive pulmonary disease (COPD) with hypercapnia.⁹ Long term CVD-OSA treatment trials are currently underway.

Pharmacological agents

Pharmacological agents known to impair respiratory drive or motor tone (eg. benzodiazepines, anti-epileptics, corticosteroids, narcotics) or cause upper airway dryness and impair surface tension (eg. anticholinergic agents and antidepressants with anticholinergic side effects) may cause OSA and should be considered for further investigation, depending on symptoms.

Figure 2. The Mallampati scale, originally used to predict ease of intubation. Higher scores (C–D) are associated with an increased incidence of sleep apnoea. Scoring is performed without phonation



Obesity

Obesity is the most significant risk factor for OSA. Increasing body mass index, neck circumference and waist-to-hip ratio are all associated with increased prevalence of OSA.^{20,21} Importantly, obesity is a controllable risk factor and weight reduction results in improvement of OSA, especially in those patients undergoing bariatric surgery. Obesity is also associated with many cardiovascular risk factors which, combined with OSA, can result in significant morbidity and mortality.

Unstable general medical conditions

Hospital patients in whom to consider OSA are those presenting multiple times for the same problem, such as acute exacerbation of COPD or chronic heart failure (CHF), particularly if present with hypercapnia and responsive to noninvasive ventilation. Patients assessed as 'difficult to intubate' by an anaesthetist should also be considered (*Figure 2*). Unexplained polycythaemia is another common sequelae of untreated OSA.

Clinical examination

The clinical examination of patients with possible OSA should include:

- estimate sleep duration
- estimate Epworth Sleepiness Scale (*Table 1*)
- assess nasal patency and sinus disease
- assess upper airway – Mallampati score (*Figure 2*), state of dentition, hard palate
- measure neck circumference/shirt collar size (>42 cm in males, >39 cm in females increases the risk of OSA)
- check blood pressure
- reassess medications.

Which investigation?

The investigation for OSA should include the monitoring of sound, airflow, respiratory effort, sleep, body position and cardiac function. Unfortunately a monitor that would do all these accurately, inexpensively and with simplicity and durability does not as yet exist. While there has been a rapid development of diagnostic tests for OSA, many are devoid of quality assurance and comparative testing.

Levels of investigation

There are four levels of investigation. A diagnosis of OSA should be made from a combination of history, examination, a test (one of level 1–4 below), and occasionally, a trial of therapy.

Level 1

Laboratory 'attended' polysomnography: useful to confirm a diagnosis absolutely. Also assists in determining other forms of sleep disordered breathing (eg. Cheyne-Stokes respiration, hypoventilation disorder) and is helpful in patients who are less coordinated. Is often considered the 'gold standard' and additional monitoring (eg. infrared video monitoring, transcutaneous CO₂, continuous systemic BP, oesophageal pressure, multiple sleep or wakefulness latency



testing) can be utilised. Currently funded by Medicare Australia. Test failure rate = <0.01%.

(NB: Test failure rate = percentage of tests performed in which inadequate information is collected to make a diagnosis – usually the result of technical difficulties, eg. electrodes dislodging, battery failure, patient error in managing equipment.)

Level 2

Home 'unattended' polysomnography: basic polysomnography with patient setting themselves up with the aid of detailed instructions (eg. DVD). Currently, interim Medicare funding is available. Test failure rates are modestly high (<15%), thus requiring repeat testing.

Level 3

Cardiopulmonary monitoring: airflow, respiratory effort, oximetry and electrocardiogram (ECG) are monitored either at home or in the hospital setting. Ideally suited to moderately high risk OSA patients or in patients in whom Cheyne-Stokes respiration or cardiac arrhythmias associated with OSA are suspected. No Medicare funding is available. Test failure rate = <5%.

Level 4

Single channel cardiopulmonary monitoring (eg. oximetry [SpO₂ and heart rate] and/or airflow): ideal to 'rule in' OSA for patients in whom OSA is highly suspected. As false negative results can occur, it should not be used to 'rule out' OSA. No Medicare funding is available. Test failure rate = 1%.

Management

A patient's life stage will often give a good indication of the underlying cause of their OSA (*Table 2*). The majority of patients are middle aged, for whom initial lifestyle management should include:

- caution about alcohol intake (<7 drinks per week)
- antismoking advice
- avoidance of sleep deprivation
- initiation of nasal steroids for a 4 week trial
- consideration of positional therapy: sleep in nonsupine position (recovery position), use one pillow and raise head of bed 10 cm, and
- initiation of a weight loss program.

A referral for a sleep study should be considered if signs or symptoms of OSA persist after a period of lifestyle management.

Surgery


In children, tonsillectomy with adenoidectomy has a role as the soft tissues are disproportionately greater than the bony airway size (*Figure 3*).²² In adults, bariatric surgery may have a role in reducing obesity – before and after studies suggest amelioration of OSA rather than abolition.²³ A multicentered trial is underway in Australia with results expected in 2011.

Nasal decongestive surgery or tonsillectomy with adenoidectomy should be considered where soft tissue abnormalities exist.

Table 2. Lifestyle indications of causes of OSA

Age	Cause	Best treatment
Children/adolescents	Anatomical	Surgical
Middle aged patients	Lifestyle/weight	<ul style="list-style-type: none"> • Lifestyle change • Weight loss • Mandibular advancement splints • CPAP • Surgery
Older patients	<ul style="list-style-type: none"> • Drugs • Medical conditions • Lifestyle/weight 	<ul style="list-style-type: none"> • Rationalise drugs if possible • Treat underlying condition • Lifestyle change/weight loss • CPAP • Mandibular advancement splints • Surgery

Figure 3. Graph of upper airway and soft tissue dimensions in 41 children, followed with sequential lateral cephalograms, and indicating the small upper airway size relative to soft tissue before 11 years of age, suggesting a relative predisposition to airway closure with tonsillar and adenoid hypertrophy²²



Jaw advancement and maxillary expansion surgery should be considered where bony abnormalities exist.

Uvullectomy, which showed much promise in the 1980s, has not proven to be of long term benefit and has significant complications, most importantly difficulty tolerating CPAP later in life.

Overall, surgery has the greatest impact in the young where an anatomical abnormality is present.

Dental splints

Designed to either hold the mandible forward or to widen the hard palate, there are a range of dental splints available and these are smaller than a tennis ball in size. Suitable patients should have mild to moderate OSA, minimal hypoxemia, adequate nasal patency, good dentition, healthy temporomandibular joints, and an absence of significant cardiovascular disease. In selected populations, the success rate can be as high as 70%. However, splint cost (\$1500–2000), longevity (~2 years) and side effects (dental pain and movement, excessive salivation, temporomandibular joint pain) may limit their use.



Figure 4. Potential complications of a poorly fitting mask



Continuous positive airway pressure

Developed in the early 1900s and rediscovered and made portable for domiciliary use in the 1980s, continuous positive airway pressure (CPAP) has been effective in managing moderate to severe OSA. It has also been used to treat acute pulmonary oedema in the hospital environment.

Several CPAP variants have been developed, such as bilevel positive airway pressure, to treat acute and chronic hypercapnic respiratory failure from many causes such as neuromuscular disease, COPD, and kyphoscoliosis. The engineering behind CPAP has also been developed to assist patient comfort, eg. auto-titrating CPAP, expiratory pressure relief, humidification and pressure ramping, as well as to treat more complex sleep apnoeas such as Cheyne-Stokes respiration.

Most pumps have inbuilt hour meters to assess usage objectively; others have built in computers which analyse mask leak, night-to-night usage, snoring, and apnoeas and hypopnoeas. Thus adherence and compliance to treatment can be measured objectively. Pumps are lightweight (<2 kg), small (<2000 cc) and operationally quiet (<35 dB). Developments in mask technology have produced external nasal, oral, oro-nasal, facial and total head (hood) masks.

Circumstances in which CPAP users might require special attention include while camping, on overseas travel and while travelling on an aeroplane. Most pumps are multi-voltage and can be used anywhere that has an electricity supply. Travelling patients should be reminded to take an extension cord and a local power point adapter. Inflight use of CPAP varies with airlines and patients should be advised to contact their airline before travel. Continuous positive airway pressure pumps can be carried as hand luggage.

Complications of CPAP are not uncommon: pump breakdown (after 5–10 years use) as well as mask and tubing decay (after 1–2 years) occur, therefore it is advisable that patients have their pump checked by a CPAP distributor or sleep centre at least annually. Acute rhinitis, dermatitis and pressure sores do occur (Figure 4). Humidification and/or nasal corticosteroids and alteration of CPAP pressure and/or mask should be considered respectively. Occasionally nasal decongestive surgery can assist adherence to CPAP. Most patients can cope if given support, and GPs play an important role in both recognising a need for, and providing, this support. Further support can be provided via a multidisciplinary approach.

Conclusion

Management of OSA is a long term commitment for both patients and their clinicians. It is imperative that the physician takes an ongoing interest in determining that the patient's (or partner's) concerns have been adequately dealt with. Importantly, more than one diagnosis may be apparent and, if so, a multi-pronged approach may be required.

Conflict of interest: none declared.

References

1. Kushida CA, Nichols DA, Simon RD, et al. Symptom-based prevalence of sleep disorders in an adult primary care population. *Sleep Breath* 2000;4:9–14.
2. Marshall NS, Bartlett DJ, Matharu KS, Williams A, Grunstein RR. Prevalence of treatment choices for snoring and sleep apnea in an Australian population. *J Clin Sleep Med* 2007;3:695–9.
3. Koskenvuo M, Kaprio J, Telakivi T, Partinen M, Heikkilä K, Sarna S. Snoring as a risk factor for ischaemic heart disease and stroke in men. *BMJ (Clin Res Ed)* 1987;294:16–9.
4. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993;328:1230–5.
5. Bearpark H, Elliott L, Grunstein R, et al. Snoring and sleep apnea. A population study in Australian men. *Am J Respir Crit Care Med* 1995;151:1459–65.
6. Ali NJ, Pitson DJ, Stradling JR. Snoring, sleep disturbance, and behaviour in 4–5 year olds. *Arch Dis Child* 1993;68:360–6.
7. Marcus CL. Sleep-disordered breathing in children. *Am J Respir Crit Care Med* 2001;164:16–30.
8. Crummy F, Piper AJ, Naughton MT. Obesity and the lung: 2. Obesity and sleep-disordered breathing. *Thorax* 2008;63:738–46.
9. Hamilton GS, Solin P, Naughton MT. Obstructive sleep apnoea and cardiovascular disease. *Intern Med J* 2004;34:420–6.
10. Wellman A, Jordan AS, Malhotra A, et al. Ventilatory control and airway anatomy in obstructive sleep apnea. *Am J Respir Crit Care Med* 2004;170:1225–32.
11. Lee SA, Amis TC, Byth K, et al. Heavy snoring as a cause of carotid artery atherosclerosis. *Sleep* 2008;31:1207–13.
12. Grunstein RR, Stenlöf K, Hedner JA, Sjöström L. Impact of self-reported sleep-breathing disturbances on psychosocial performance in the Swedish Obese Subjects (SOS) Study. *Sleep* 1995;18:635–43.
13. Crummy F, Kossman T, Cameron P, Swann P, Naughton MT. Prevalence of sleepiness in surviving drivers of motor vehicle collisions. *Intern Med J* 2008;38:769–75.
14. Kennedy JD, Blunden S, Hirte C, et al. Reduced neurocognition in children who snore. *Pediatr Pulmon* 2004;37:330–7.
15. Capdevila OS, Kheirandish-Gozal L, Dayyat E, Gozal D. Pediatric obstructive sleep apnea: complications, management, and long-term outcomes. *Proceedings of the American Thoracic Society* 2008;5:274–82.
16. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep* 2008;31:1071–8.
17. Marshall NS, Wong KKH, Liu PY, Cullen SRJ, Knudman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. *Sleep* 2008;31:1079–85.
18. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005;353:2034–41.
19. Marin JM, Carrizo SJ, Vicente E, Agustí AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005;365:1046–53.
20. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA* 2000;284:3015–21.
21. Davies RJ, Ali NJ, Stradling JR. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. *Thorax* 1992;47:101–5.
22. Jeans WD, Fernando DC, Maw AR, Leighton BC. A longitudinal study of the growth of the nasopharynx and its contents in normal children. *Br J Radiol* 1981;54:117–21.
23. Lettieri CJ, Eliasson AH, Greenburg DL. Persistence of obstructive sleep apnea after surgical weight loss. *J Clin Sleep Med* 2008;4:333–8.